You are here

  • Home
  • Archive
  • Volume 19, Issue 2
  • Systematic review suggests TNF-α inhibitors may be rational options for pregnant patients with inflammatory bowel disease

Article Text

Article menu
Download PDFPDF
Harms
Systematic review
Systematic review suggests TNF-α inhibitors may be rational options for pregnant patients with inflammatory bowel disease
  1. Barrett G Levesque1,
  2. Marlene E Pountney-Levesque2
  1. 1Division of Gastroenterology, University of California San Diego, La Jolla, California, USA;
  2. 2North County Health Center, San Diego, California, USA
  1. Correspondence to: Barrett G Levesque, Division of Gastroenterology, University of California San Diego, 9500 Gilman Dr #0956, La Jolla, CA 92093, USA; bglevesque{at}ucsd.edu

https://doi.org/10.1136/eb-2013-101536

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Nielsen OH, Loftus EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med 2013;11:174.OpenUrlCrossRefPubMed

    Context

    The diagnosis of inflammatory bowel disease (IBD) overlaps with the reproductive years in many patients’ lives. Therefore, there is an important need for valid data to support medical decision-making around conception planning and pregnancy in IBD. Given that tumour necrosis factor α (TNF-α) inhibitors are highly effective options for inducing and maintaining a clinical remission, their risks and benefits need to be well understood in the context of maternal and fetal outcomes. This systematic review addresses the risk of adverse birth outcomes due to maternal TNF-α inhibitor therapy.

    Methods

    This was a well-conducted review of all currently available studies of the risks of TNF-α therapy in pregnant patients. Study types included case–control studies, case series and case reports. Investigators assessed …

    View Full Text

    Footnotes

    • Competing interests BGL reports personal fees from Prometheus Labs, personal fees from Santarus Inc, personal fees from UCB Pharma, personal fees from Warner Chilcott and personal fees from Salix, outside the submitted work.